Company intelligence / Profile preview
HaemaLogiX
Woolloomooloo/Sydney, New South Wales, Australiahaemalogix.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 2
01
Overview
KappaMab, the lead monoclonal antibody targeting KMA, has shown excellent safety and efficacy in relapsed/refractory multiple myeloma patients. Interim Phase IIb data validate its potential to boost standard-of-care treatments with a favorable safety profile. Final results were anticipated late in 2021. The company also holds exclusivity over both the targets and their corresponding antibodies, strengthening its IP position
- Therapeutic areas
- OncologyHematology
- Modalities
- monoclonal antibodies (mAbs)autologous CAR-T cellsbispecific antibodies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Strategic partnerships for commercialization are a stated goalPlatinum Asset Management invested as an institutional investorCollaborations with leading academic centers globally in MM & AL Amyloidosis therapy
Beyond the preview
Go deeper on HaemaLogiX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HaemaLogiX.